Neoadjuvant vismodegib is not recommended to be available as a routinely commissioned treatment option for locally advanced basal cell carcinoma (BCC) prior to curative treatment for lesions likely to result functional sequelae or significant aesthetic sequelae within the criteria set out in this document. Patients must be suitable or potentially suitable for curative treatment at baseline.

The policy is restricted to certain age groups as there is insufficient evidence to confirm safety and/or it is not recommended through the licence authorisation process to be used in those age groups not included in the policy.